2023
Biological treatment for bullous pemphigoid
Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A, Baum S. Biological treatment for bullous pemphigoid. Frontiers In Immunology 2023, 14: 1157250. PMID: 37180101, PMCID: PMC10172582, DOI: 10.3389/fimmu.2023.1157250.Peer-Reviewed Original ResearchMeSH KeywordsAdultHumansImmunosuppressive AgentsOmalizumabPemphigoid, BullousRituximabSkin Diseases, VesiculobullousConceptsBullous pemphigoidImmunosuppressive therapyPatients treated with rituximabLong-term corticosteroid useAdjuvant immunosuppressive therapyConventional immunosuppressive therapySteroid-sparing agentsAutoimmune subepidermal bullous diseaseFirst-line treatmentPrevious treatment failuresSeries of patientsFollow-up periodFollow-up visitSignificant side effectsNo adverse eventsSubepidermal bullous diseasesBP durationRecalcitrant BPRituximab coursesSystemic corticosteroidsClinical responseTreatment failureCorticosteroid useImmunobiological therapyBiologic therapy
2016
Is There a Role for Opportunistic Infection Prophylaxis in Pemphigus? An Expert Survey
Leshem Y, Snast I, Friedland R, Atzmony L, Levi A, Hodak E, Mimouni D. Is There a Role for Opportunistic Infection Prophylaxis in Pemphigus? An Expert Survey. American Journal Of Clinical Dermatology 2016, 18: 127-132. PMID: 27826815, DOI: 10.1007/s40257-016-0233-1.Peer-Reviewed Original ResearchMeSH KeywordsHealth Care SurveysHumansImmunosuppressive AgentsMass ScreeningOpportunistic InfectionsPemphigusPractice Guidelines as TopicPractice Patterns, Physicians'ConceptsOpportunistic infection prophylaxisImmunosuppressive therapyInfection prophylaxisInitiation of immunosuppressive therapyEffects of immunosuppressive therapyAdverse effects of immunosuppressive therapyEmergence of resistant pathogensCessation of immunosuppressionHistory of OIInfectious disease specialistsDrug of choiceTertiary care settingBackgroundOpportunistic infectionsImmunosuppressive agentsImmunosuppressive conditionsRisk stratificationDisease specialistsFrequent drugsResistant pathogensSide effectsSevere diseaseHepatitis virusObjectiveOur objectivePatientsPemphigus
2015
The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis
Atzmony L, Hodak E, Leshem Y, Rosenbaum O, Gdalevich M, Anhalt G, Mimouni D. The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis. Journal Of The American Academy Of Dermatology 2015, 73: 264-271. PMID: 26088689, DOI: 10.1016/j.jaad.2015.04.038.Peer-Reviewed Original ResearchConceptsRisk of relapseRandomized controlled trialsMeta-analysis of randomized controlled trialsControlled trialsCumulative glucocorticoid doseOral glucocorticoid treatmentMeta-analysisTreatment of pemphigusSystematic reviewDisease controlGlucocorticoid doseOral glucocorticoidsIntravenous immunoglobulinMycophenolate mofetilPemphigus treatmentAdjuvant therapyPlasma exchangeAdjuvant modalitiesGlucocorticoid treatmentAdverse eventsPemphigus vulgarisPrimary outcomeRelapseSecondary outcomesTen trials
2014
Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus: A Systematic Review and Meta-Analysis
Atzmony L, Hodak E, Gdalevich M, Rosenbaum O, Mimouni D. Treatment of Pemphigus Vulgaris and Pemphigus Foliaceus: A Systematic Review and Meta-Analysis. American Journal Of Clinical Dermatology 2014, 15: 503-515. PMID: 25403548, DOI: 10.1007/s40257-014-0101-9.Peer-Reviewed Original ResearchConceptsSteroid-sparing effectRemission rateRandomized controlled trialsControlled trialsTreatment modalitiesPemphigus vulgarisTreatment of pemphigus vulgarisTopical epidermal growth factorComplete response ratePemphigus foliaceusCochrane Central Register of Controlled TrialsOptimal therapeutic approachIncreased remission ratesCentral Register of Controlled TrialsMulticenter randomized controlled trialShort-term efficacyRegister of Controlled TrialsCase-control studyMeta-analysesCochrane Central RegisterSteroid-sparingIntravenous immunoglobulinOpen-labelSustained remissionEpidermal growth factor